Aquestive Therapeutics is trading 10.1% down now at $4.14 on October 15, 2026, with no clear company-specific catalyst identified for the decline. - The company announced FDA acceptance of Anaphylm’s NDA resubmission and a March 16, 2027 PDUFA date. - Reporting does not connect that positive update to the selloff. - Biotech shares are higher, so sector weakness does not explain the move.